Page 44 - Express Scripts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ -- Today, Prime Therapeutics LLC/Magellan Rx Management LLC (Prime/MRx) announces that it has appointed Ken Bodmer as chief financial officer...

The biggest U.S. drugstore chain aims to make the payment system more transparent by using a formula based on a drug's cost, a fixed markup, and a fee that reflects the value of the pharmacy services, the company said Tuesday.

The industry is moving away from a traditional, complex pricing model and toward the “cost-plus” approach introduced by billionaire Mark Cuban at his pharmacy company.

(Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's rival obesity drug Wegovy to hit around $7.5 billion. Pfizer last week said it would not advance its highly-anticipated oral obesity drug danuglipron into late-stage clinical trials after most patients dropped out of a midstage trial with high ...

Policymakers: “Middlemen” between drugmakers and retailers pocket profits to detriment of consumers.